Breviscapine reduces acute lung injury induced by left heart ischemic reperfusion in rats by inhibiting the expression of ICAM-1 and IL-18
- Authors:
- Yuxia Wang
- Mingli Ji
- Liping Chen
- Xinjun Wu
- Lei Wang
View Affiliations
Affiliations: Department of Pathophysiology, Xinxiang Medical University, Xinxiang, Henan 453003, P.R. China, Department of General Surgery, The First Affiliated Hospital of Xinxiang Medical University, Weihui, Henan 453100, P.R. China
- Published online on: September 4, 2013 https://doi.org/10.3892/etm.2013.1287
-
Pages:
1322-1326
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
It has been demonstrated that breviscapine is able to treat coronary disease and reduce the inflammatory response; however, there are no relevant reports concerning its effects on the expression of inflammatory factors in acute lung injury induced by left heart ischemic reperfusion and the underlying mechanisms. In this study, we created a left heart ischemia‑reperfusion model in rats to investigate the effects of breviscapine on the expression of interleukin 18 (IL-18) and intercellular adhesion molecule-1 (ICAM-1), as well as to determine the possible mechanisms involved in the protective effects of breviscapine on respiratory function. The left heart ischemia‑reperfusion model was created by ligating the anterior descending branch of the coronary artery for 30 mins followed by reperfusion. Rats in the treatment group (TG) were treated with breviscapine (10 mg/kg) and the rats in the control group (CG) received normal saline. Ten rats in the two groups were sacrificed at three points: 30 min after ligating (T1), 30 min after reperfusion (T2) and 60 min after reperfusion (T3). A respiration curve was produced and the arterial partial pressure of oxygen (PaO2) was measured for all rats. Additionally, the expression levels of IL-18 and ICAM-1 were determined and the correlation between IL-18 and ICAM-1 expression in lung tissue was analyzed. The level of IL-18 in peripheral blood and bronchialalveolar lavage fluid (BALF) was also measured. The respiration amplitude was lower and the duration time was shorter in the TG rats than in the CG rats at T1, T2 and T3. The expression levels of IL-18 and ICAM-1 in the TG group were clearly reduced. The level of IL-18 in the peripheral blood and BALF was downregulated following the administration of breviscapine. These results demonstrate that breviscapine inhibits the expression of IL-18 and ICAM-1, thereby protecting the lungs from inflammatory cascade responses.
View Figures |
Figure 1
|
 |
Figure 2
|
 |
Figure 3
|
 |
Figure 4
|
 |
Figure 5
|
 |
Figure 6
|
 |
Figure 7
|
View References
|
1.
|
Ji M, Qian Z, Song X and Wang Y: An animal
model of acute lung injury induced by left heart
ischemia-reperfusion. Chin J Pathophysiol. 27:1453–1456. 2011.(In
Chinese).
|
|
2.
|
van de Veerdonk FL, Netea MG, Dinarello CA
and Joosten LA: Inflammasome activation and IL-1β and IL-18
processing during infection. Trends Immunol. 32:110–116. 2011.
|
|
3.
|
Chen J, Zhao YH, Liu XL, Chen XL, Li J,
Lian QQ, et al: Effects of breviscapine on pulmonary inflammatory
response and lung injury in children undergoing open heart surgery.
J Asian Nat Prod Res. 14:270–275. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Xie WX, Yue LM and Song HL: Protective
effect of breviscapine on cardiac function in children after
cardiopulmonary bypass undergoing open heart surgery. Zhongguo
Zhong Xi Yi Jie He Za Zhi. 30:264–267. 2010.(In Chinese).
|
|
5.
|
Zhang MY, Fan SJ, Li LP, Wu BY and Wang Y:
The anti-injury effect of breviscapine injection on the hypoxic
ischemic brain damage of neonatal rats and the expression of Bcl-2
and Bax. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 27:196–200.
2011.(In Chinese).
|
|
6.
|
Barker BR, Taxman DJ and Ting JP:
Cross-regulation between the IL-1β/IL-18 processing inflammasome
and other inflammatory cytokines. Curr Opin Immunol. 23:591–597.
2011.
|
|
7.
|
Volin MV and Koch AE: Interleukin-18: a
mediator of inflammation and angiogenesis in rheumatoid arthritis.
J Interferon Cytokine Res. 31:745–741. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Nishimoto N: Interleukin-6 as a
therapeutic target in candidate inflammatory diseases. Clin
Pharmacol Ther. 87:483–487. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Pedroza M, Schneider DJ and
Karmouty-Quintana H: Interleukin-6 contributes to inflammation and
remodeling in a model of adenosine mediated lung injury. PLoS One.
6:e226672011. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Yokomura I, Iwasaki Y, Nagata K, et al:
Role of intercellular adhesion molecule-1 in acute lung injury
induced by candidemia. Exp Lung Res. 27:417–411. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Porter JC and Hall A: Epithelial ICAM-1
and ICAM-2 regulate the egression of human T cells across the
bronchial epithelium. FASEB J. 23:492. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Gustapane M, Cardillo MT, Biasillo G and
Biasucci LM: Myeloperoxidase as possible diagnostic and prognostic
marker of acute coronary syndrome. Recenti Prog Med. 102:447–450.
2011.(In Italian).
|
|
13.
|
Ramirez P, Ferrer M, Gimeno R, et al:
Systemic inflammatory response and increased risk for
ventilator-associated pneumonia: a preliminary study. Crit Care
Med. 37:1691–1615. 2009. View Article : Google Scholar : PubMed/NCBI
|
